Differences in monocyte-to-lymphocyte ratio of patients with cervical cancer at dr. Ramelan Central Naval Hospital, Surabaya before and after chemoradiation therapy from January 2020 to July 2023
Monocyte-to-lymphocyte ratio in cervical cancer
DOI:
https://doi.org/10.59747/smjidisurabaya.v2i1.39Keywords:
Cervical cancer, chemoradiation, human & medicine, MLR, monocyte-to-lymphocyte ratioAbstract
Background: Cervical cancer is a gynecological malignancy resulting from abnormal and unregulated proliferation of cells, which impairs growth, differentiation, and apoptosis of the cells. Cervical cancer is the second most prevalent disease and is responsible for approximately 10 million deaths in 2020. A number of studies have reported that the monocyte-to-lymphocyte ratio (MLR) may be a useful indicator of the prognosis of patients diagnosed with cervical cancer. Objective: This study aims to determine the differences in monocyte-to-lymphocyte ratio of patients with cervical cancer before and after chemoradiation therapy. Materials and Methods: This study used an analytical observational design with secondary data from 62 patients at dr. Ramelan Central Naval Hospital, Surabaya between January 2020 and July 2023. The sample was taken using a consecutive sampling technique. The variables included patients with stage IIB cervical cancer stage and higher who underwent chemoradiation therapy as well as the monocyte-to-lymphocyte ratio (MLR) of the patients before and after chemoradiation therapy. Results: The results of the Wilcoxon signed-rank test indicated that the therapy had an effect on the MLR of patients with stage IIB cervical cancer and higher, with a p-value of less than 0.001. Conclusion: Significant differences were observed in the MLR of patients with cervical cancer before and after chemoradiation therapy.
References
Abu-Shawer, O., Abu-Shawer, M., Hirmas, N., Alhouri, A., Massad, A., Alsibai, B., Sultan, H., Hammo, H., Souleiman, M., Shebli, Y., 2019. Hematologic markers of distant metastases and poor prognosis in gynecological cancers. BMC Cancer 19, 1–8.
Ao, M., Li, P., Sun, D., Li, X., Xu, S., Hao, Y., 2023. Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy. J. Obstet. Gynaecol. (Lahore). 43.
Aulia, M.P., Hartanti, M.D., 2023. The Effect of Cervical Cancer Counseling on Cervical Cancer Prevention Behavior in Women of Childbearing Age: A Literature Study. J. Kedokt. Diponegoro (Diponegoro Med. Journal) 12, 283–292.
Bagheri, Y., Babaha, F., Falak, R., Yazdani, R., Azizi, G., Sadri, M., Abolhassani, H., Shekarabi, M., Aghamohammadi, A., 2019. IL-10 induces TGF-β secretion, TGF-β receptor II upregulation, and IgA secretion in B cells. Eur. Cytokine Netw. 30, 107–113.
Bashir, H., Ahmad Bhat, S., Majid, S., Hamid, R., Koul, R.K., Rehman, M.U., Din, I., Ahmad Bhat, J., Qadir, J., Masood, A., 2020. Role of inflammatory mediators (TNF-α, IL-6, CRP), biochemical and hematological parameters in type 2 diabetes mellitus patients of Kashmir, India. Med. J. Islam. Repub. Iran 34, 5.
Chen, L., Zhang, F., Sheng, X., Zhang, S., 2015. Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1–IIa cervical cancer patients who undergo radical surgery. Onco. Targets. Ther. 1355–1362.
Dasari, S., Wudayagiri, R., Valluru, L., 2015. Cervical cancer: Biomarkers for diagnosis and treatment. Clin. Chim. acta 445, 7–11.
Feng, F., Zheng, G., Wang, Q., Liu, S., Liu, Z., Xu, G., Wang, F., Guo, M., Lian, X., Zhang, H., 2018. Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer. BMC Gastroenterol. 18, 148.
Huang, H., Liu, Q., Zhu, L., Zhang, Y., Lu, X., Wu, Y., Liu, L., 2019. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci. Rep. 9, 3284.
Jain, A., Bobdey, S., Sathwara, J., Ganesh, B., Saoba, S., Khan, A., 2016. Role of monocyte and lymphocyte counts in prognosis of cervical cancer. Int. J. Reprod. Contraception, Obstet. Gynecol. 5, 2244.
Li, Y.-X., Chang, J.-Y., He, M.-Y., Wang, H.-R., Luo, D.-Q., Li, F.-H., Li, J.-H., Ran, L., 2021. Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer. J. Oncol. 2021, 2939162.
Moeini, P., Niedźwiedzka-Rystwej, P., 2021. Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment. Int. J. Mol. Sci. 22, 30–33.
Olingy, C.E., Dinh, H.Q., Hedrick, C.C., 2019. Monocyte heterogeneity and functions in cancer. J. Leukoc. Biol. 106, 309–322.
Patysheva, M., Frolova, A., Larionova, I., Afanas’ev, S., Tarasova, A., Cherdyntseva, N., Kzhyshkowska, J., 2022. Monocyte programming by cancer therapy. Front. Immunol. 13.
Prabawa, I.P.Y., Bhargah, A., Liwang, F., Tandio, D.A., Tandio, A.L., Lestari, A.A.W., Budiana, I.N.G., Manuaba, I.B.A.P., 2019. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pacific J. cancer Prev. APJCP 20, 863.
Richards, D.M., Hettinger, J., Feuerer, M., 2013. Monocytes and macrophages in cancer: Development and functions. Cancer Microenviron. 6, 179–191.
Schegoleva, A.A., Khozyainova, A.A., Gerashchenko, T.S., Zhuikova, L.D., Denisov, E. V., 2022. Metastasis prevention: targeting causes and roots. Clin. Exp. Metastasis 39, 505–519.
Tan, D., Fu, Y., Tong, W., Li, F., 2018. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: A meta-analysis. Int. J. Surg. 55, 128–138.
Trinh, H., Dzul, S.P., Hyder, J., Jang, H., Kim, S., Flowers, J., Vaishampayan, N., Chen, J., Winer, I., Miller, S., 2020. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT). Clin. Chim. Acta 510, 711–716.
Wang, Q., Qiao, W., Liu, B., Li, J., Yuan, C., Long, J., Hu, C., Zang, C., Zheng, J., Zhang, Y., 2022. The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy. BMC Gastroenterol. 22, 1–11.
Whiteside, T.L., 2022. Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression. Exp. Suppl. 113, 89–106.
Xiang, J., Zhou, L., Li, X., Bao, W., Chen, T., Xi, X., He, Y., Wan, X., 2017. Preoperative monocyte-to-lymphocyte ratio in peripheral blood predicts stages, metastasis, and histological grades in patients with ovarian cancer. Transl. Oncol. 10, 33–39.
Xu, Z., Zhang, J., Zhong, Y., Mai, Y., Huang, D., Wei, W., Huang, J., Zhao, P., Lin, F., Jin, J., 2021. Predictive value of the monocyte-to-lymphocyte ratio in the diagnosis of prostate cancer. Med. (United States) 100, 1–6.
Ye, L., Zhou, G., Zhou, L., Wang, D., Xiong, S., Liu, C., Zhang, G., 2023. Diagnostic roles of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein, and cancer antigen 125 for ovarian cancer. J. Int. Med. Res. 51, 03000605231218557.
Zhang, X., Zeng, Q., Cai, W., Ruan, W., 2021. Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. BMC Public Health 21, 1–10.
Zhao, J., Huang, W., Wu, Y., Luo, Y., Wu, B., Cheng, J., Chen, J., Liu, D., Li, C., 2020. Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: A systematic review and meta-analysis. Cancer Cell Int. 20, 1–14.
Zhu, M., Feng, M., He, F., Han, B., Ma, K., Zeng, X., Liu, Z., Liu, X., Li, J., Cao, H., 2018. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer. Clin. Chim. acta 483, 296–302.
Downloads
Published
License
Copyright (c) 2024 Stella Yuanita Husodo, Ketut Edy Sudiarta, R. Varidianto Yudho
This work is licensed under a Creative Commons Attribution 4.0 International License.
